American College of Radiology (ACR) resources can help radiology professionals safely and effectively provide, and receive payment for CT lung cancer screening. Demand for this care will grow quickly now that Medicare has proposed to cover high-risk seniors for these lifesaving exams.

Third-generation CT scanners have been shown to be capable of generating high-quality contrast images while delivering lower doses of ionizing radiation than their predecessors, according to a study published in Radiology.

Yet another blood test for Alzheimer's disease is being developed--this time by a group of Japanese researchers. The technique could, if approved, be used to screen patients who show no signs of neurodegeneration. 

More than half of surveyed referring physicians said that F-18 FDG PET/CT scans were being clinically misinterpreted in somewhere between 5 percent and 20 percent of cases, according to a study published Nov. 7 in the Journal of Nuclear Medicine.

The Cambridge, Mass.-based pharmaceutical development company NeuroPhage, which specializes in novel drugs for neurodegenerative disease announced last week that Franz Hefti, PhD, would take the lead as president and chief operating officer.

In a long-awaited decision, the Centers for Medicare & Medicaid Services (CMS) issued a draft proposal that extended coverage of annual low-dose CT screening to Medicare beneficiaries at high risk for lung cancer.

When it comes to diagnosing appendicitis in adult patients, recent research has found that despite CT radiation concerns, life expectancy loss across various imaging modalities was so small that paradigm shifts in radiology were found unnecessary.

New York City-based Anavex Life Sciences has developed an investigational treatment for Alzheimer's called Anavex 2-73, and announced Nov. 7 that the company would be working with Neuronetrix to take the drug through a phase IIa clinical trial.